GSK plc (LON:GSK) Receives Consensus Recommendation of “Hold” from Analysts

GSK plc (LON:GSK) has been assigned an average recommendation of “Hold” from the seven analysts that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is GBX 1,917.86.

A number of equities research analysts recently commented on the company. Shore Capital Group reiterated a “buy” rating and issued a GBX 2,300 price objective on shares of GSK in a report on Wednesday, February 4th. JPMorgan Chase & Co. restated an “underweight” rating on shares of GSK in a report on Wednesday, January 7th. Deutsche Bank Aktiengesellschaft boosted their target price on GSK from GBX 1,600 to GBX 1,675 and gave the stock a “hold” rating in a research report on Thursday, January 15th. Citigroup upped their price target on GSK from GBX 1,900 to GBX 2,250 and gave the company a “buy” rating in a research note on Monday, February 9th. Finally, Berenberg Bank increased their price target on shares of GSK from GBX 1,600 to GBX 1,660 and gave the company a “hold” rating in a research report on Monday, November 24th.

Insider Buying and Selling at GSK

In other news, insider Wendy Becker bought 3,334 shares of the business’s stock in a transaction on Friday, February 20th. The shares were bought at an average cost of GBX 2,219 per share, for a total transaction of £73,981.46. Also, insider Luke Miels sold 15,579 shares of GSK stock in a transaction on Friday, February 13th. The stock was sold at an average price of GBX 2,160, for a total transaction of £336,506.40. Over the last 90 days, insiders bought 7,931 shares of company stock valued at $16,480,489. Corporate insiders own 0.26% of the company’s stock.

GSK Price Performance

GSK opened at GBX 2,035 on Friday. The company has a fifty day moving average price of GBX 2,013.54 and a two-hundred day moving average price of GBX 1,794.17. The firm has a market capitalization of £81.63 billion, a PE ratio of 14.66, a P/E/G ratio of 1.24 and a beta of 0.32. GSK has a 52 week low of GBX 1,242.50 and a 52 week high of GBX 2,282. The company has a debt-to-equity ratio of 108.20, a quick ratio of 0.73 and a current ratio of 0.82.

GSK (LON:GSK) last posted its quarterly earnings results on Wednesday, February 4th. The company reported GBX 172 earnings per share for the quarter. GSK had a return on equity of 37.19% and a net margin of 17.50%. As a group, analysts anticipate that GSK will post 175.980975 earnings per share for the current year.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.